DXCM Dexcom Inc

Price (delayed)

$563.14

Market cap

$54.48B

P/E Ratio

101.1

Dividend/share

N/A

EPS

$5.57

Enterprise value

$55.16B

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights
Dexcom's net income has soared by 159% YoY and by 3.2% from the previous quarter
The EPS has soared by 150% YoY and by 3% QoQ
The quick ratio has declined by 27% year-on-year
The stock's price to earnings (P/E) is 6% more than its last 4 quarters average of 95.0

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
96.75M
Market cap
$54.48B
Enterprise value
$55.16B
Valuations
Price to earnings (P/E)
101.1
Price to book (P/B)
27.26
Price to sales (P/S)
25.1
EV/EBIT
156.13
EV/EBITDA
126.37
EV/Sales
25.42
Earnings
Revenue
$2.17B
EBIT
$353.3M
EBITDA
$436.5M
Free cash flow
$100.5M
Per share
EPS
$5.57
Free cash flow per share
$1.04
Book value per share
$20.66
Revenue per share
$22.44
TBVPS
$46.38
Balance sheet
Total assets
$4.5B
Total liabilities
$2.51B
Debt
$1.84B
Equity
$2B
Working capital
$2.87B
Liquidity
Debt to equity
0.92
Current ratio
5.78
Quick ratio
5.11
Net debt/EBITDA
1.55
Margins
EBITDA margin
20.1%
Gross margin
69.2%
Net margin
24.5%
Operating margin
15.9%
Efficiency
Return on assets
12.5%
Return on equity
29.4%
Return on invested capital
7.7%
Return on capital employed
9.1%
Return on sales
16.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
-0.35%
1 week
2.5%
1 month
10.37%
1 year
45.81%
YTD
52.32%
QTD
31.88%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$2.17B
Gross profit
$1.5B
Operating income
$345M
Net income
$530.6M
Gross margin
69.2%
Net margin
24.5%
Dexcom's net income has soared by 159% YoY and by 3.2% from the previous quarter
The net margin has soared by 106% YoY but it has decreased by 3.5% from the previous quarter
DXCM's gross profit is up by 37% year-on-year and by 10% since the previous quarter
DXCM's operating income is up by 33% year-on-year and by 11% since the previous quarter

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
P/E
101.1
P/B
27.26
P/S
25.1
EV/EBIT
156.13
EV/EBITDA
126.37
EV/Sales
25.42
The EPS has soared by 150% YoY and by 3% QoQ
The stock's price to earnings (P/E) is 6% more than its last 4 quarters average of 95.0
The company's equity rose by 48% YoY and by 5% QoQ
DXCM's P/B is 37% above its 5-year quarterly average of 19.9 and 29% above its last 4 quarters average of 21.1
The stock's price to sales (P/S) is 95% more than its 5-year quarterly average of 12.9 and 32% more than its last 4 quarters average of 19.0
Dexcom's revenue has increased by 26% YoY and by 7% from the previous quarter

Efficiency

How efficient is Dexcom business performance
Dexcom's ROA has soared by 60% YoY but it has decreased by 2.3% from the previous quarter
The ROE is up by 41% year-on-year but it is down by 6% since the previous quarter
DXCM's return on invested capital is down by 14% year-on-year but it is up by 10% since the previous quarter
The ROS rose by 3.8% QoQ

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 80% higher than its total liabilities
The company's total assets rose by 28% YoY and by 2.6% QoQ
The quick ratio has declined by 27% year-on-year
The debt is 8% less than the equity
The company's equity rose by 48% YoY and by 5% QoQ
DXCM's debt to equity is down by 29% YoY and by 4.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.